Welcome to our dedicated page for Baird Medical news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical stock.
Baird Medical Investment Holdings Ltd (NASDAQ: BDMD) is closely associated with minimally invasive Microwave Ablation (MWA) technology for the treatment of benign and malignant tumors. The BDMD news page on Stock Titan aggregates company-specific updates so readers can follow how Baird Medical’s medical devices and minimally invasive treatment technologies are being used and introduced in clinical settings around the world.
News about Baird Medical often highlights clinical milestones, such as first procedures in new countries, successful thyroid and liver tumor ablations, and applications of its MWA systems in bone tumor cases. Releases also describe physician training initiatives, including advanced MWA training sessions and participation in international workshops focused on thyroid microwave ablation and thermal ablation techniques.
Another recurring theme in BDMD news is global expansion and regulatory progress. The company reports regulatory approvals and product registrations in markets such as Pakistan and Vietnam, as well as entry into countries including Egypt and Bangladesh. Announcements have also covered the establishment of a U.S. manufacturing base through a partnership with MPS Medical to support worldwide supply of its proprietary technologies.
Investors and healthcare professionals can use this news feed to monitor developments related to Baird Medical’s microwave ablation devices, its presence in leading hospitals and clinics, and its broader commercialization and training activities. For ongoing insight into BDMD stock from a news perspective, this page provides a focused view of the company’s clinical, regulatory, and operational updates.
Baird Medical (NASDAQ: BDMD), a leader in minimally invasive Microwave Ablation (MWA) technology, participated in activities surrounding the 2025 J.P. Morgan Healthcare Conference in San Francisco. Following its Nasdaq debut in October 2024, the company engaged with healthcare investors and industry leaders, discussing advancements in microwave ablation technology and patient outcomes.
Chairwoman Haimei Wu highlighted the conference's importance in connecting with shareholders, innovators, and healthcare sector advisors. The company plans to utilize these interactions to support its 2025 strategic initiatives, focusing on expanding its U.S. presence and strengthening collaborations with key opinion leaders (KOLs) in medical technology.
Baird Medical (NASDAQ: BDMD) recently sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid nodule treatment. The program was led by Dr. Emad Kandil from Tulane University School of Medicine, with participation from Dr. Sean P. Nikravan and Dr. Erin H. Lin.
Participants observed seven live MWA procedures, gaining hands-on experience in precision targeting and workflow optimization. The training emphasized the technology's efficiency and potential for improved patient outcomes, including faster recovery times. Following the session, the physicians engaged in clinical discussions and received Certificates of Completion.
Chairwoman Haimei Wu emphasized the importance of hands-on training and expert collaboration in advancing MWA technology adoption for thyroid treatments.
Baird Medical (NASDAQ: BDMD), a leader in minimally invasive microwave ablation (MWA) technology, sponsored and participated in the 4th Sichuan Medical Association Thyroid Disease Academic Conference in China. The company showcased its advanced MWA technology for thyroid nodules, featuring larger ablation zones and shorter treatment times.
During the conference, which brought together prominent thyroid specialists and healthcare professionals, Baird Medical engaged in discussions with medical leaders and presented its innovative solutions. Chairwoman Haimei Wu emphasized the company's commitment to advancing thyroid disease treatment and improving patient outcomes through technological innovation and professional collaboration.
Baird Medical (NASDAQ: BDMD) participated in and supported the 2024 Guangdong Provincial Parathyroid Disease - Southern Yue Forum in Guangzhou, China. The company, specializing in minimally invasive microwave ablation (MWA) technology, showcased its innovations in endocrine care at the event.
The forum brought together medical experts, researchers, and healthcare professionals to discuss advancements in parathyroid disease diagnosis and treatment. As a sponsor, Baird Medical presented its MWA technology designed for endocrine conditions, engaging with key opinion leaders and fostering collaborations to better understand clinical needs.
Baird Medical (NASDAQ: BDMD) sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid treatment. The session was led by Dr. Emad Kandil from Tulane University School of Medicine, with participation from Dr. Salem Noureldine of George Washington University. Dr. Noureldine observed five live MWA cases and practiced advanced techniques.
Dr. Kandil, who has performed over 80 MWA procedures, recently presented at the American Thyroid Association meeting, highlighting MWA's effectiveness compared to Radiofrequency Ablation. The training emphasized MWA's efficiency and patient-centered design, notably the absence of grounding pads. Dr. Noureldine received a Certificate of Completion, preparing him to integrate MWA into clinical practice.
Baird Medical (NASDAQ: BDMD) sponsored and participated in the 2024 Guangdong Thyroid Surgery Committee Annual Meeting in Guangdong, China. The two-day event, hosted by the Guangdong Provincial Hospital of Traditional Chinese Medicine, focused on advancing thyroid disease treatment. Baird Medical showcased its microwave ablation (MWA) technology and engaged with healthcare professionals to discuss innovations in endoscopic and minimally invasive surgery.
Chairwoman Haimei Wu emphasized the meeting's importance as a platform for sharing advancements in thyroid ablation and fostering collaboration among experts. The company utilized the interactive sessions to engage with specialists about current challenges and future directions in thyroid care, reinforcing its commitment to advancing minimally invasive surgery solutions globally.
Baird Medical (NASDAQ: BDMD) recently sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid care advancement. Led by Dr. Emad Kandil from Tulane University School of Medicine, the program provided hands-on training to two endocrinologists who observed seven live MWA cases.
Dr. Kandil, who has performed over 80 MWA procedures, recently presented at the American Thyroid Association meeting, highlighting MWA's effectiveness compared to Radiofrequency Ablation. The participating physicians received Certificates of Completion, preparing them to integrate MWA into their clinical practices.
The initiative reflects Baird Medical's commitment to expanding access to minimally invasive therapies through physician education and training partnerships.
Baird Medical Group (NASDAQ: BDMD) held its 2024 Annual Review and 2025 Planning Meeting at Baird Capital Tower in Guangzhou, China. The two-day event included participation in the 7th Thyroid Disease Forum and comprehensive reviews of market performance and future strategies.
Production Manager Le Zhang presented the 2025 production schedule and plans for enhanced after-sales service. The company's leadership discussed strengthening distributor relationships to support global expansion goals. The meeting highlighted Baird Medical's recent NASDAQ listing as a milestone that increased international recognition in the minimally invasive medical technologies sector.
Baird Medical (NASDAQ: BDMD) sponsored and participated in the 2024 7th Thyroid Disease Standardized Diagnosis and Treatment Forum in Guangzhou, China. The company showcased its advanced microwave ablation (MWA) technology for thyroid treatments, which features larger ablation zones and shorter treatment times. The event, hosted by Guangdong Provincial People's Hospital, brought together leading medical experts to discuss standardized treatment protocols for thyroid diseases. Chairwoman Haimei Wu emphasized the company's commitment to advancing solutions for thyroid disease management and improving patient outcomes globally.
Baird Medical (NASDAQ: BDMD) sponsored the Surgery of the Thyroid and Parathyroid Glands Course at Massachusetts General Hospital. The event featured discussions on thyroid and parathyroid surgery advancements, with Dr. Shuhang Xu presenting on microwave ablation (MWA) technology for treating thyroid conditions. The presentation highlighted MWA's benefits, including minimally invasive approach, shorter procedures, and precise ablation capabilities. The course covered upcoming American Thyroid Association guidelines and innovations in thyroid cancer management.